Clinical Trial Update: Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating camrelizumab in combination with pegylated liposomal doxorubicin and losartan for patients with triple-negative breast cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN